Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation. Academic Article uri icon

Overview

abstract

  • Long-acting agents hold significant promise for treating and preventing common illnesses, including infections. Pharmacokinetic and safety data during pregnancy and lactation are often unavailable for new drugs; these data are vital to facilitate optimal drug use by pregnant and lactating women and women who may conceive. In this commentary, we summarize the circumstances in which pregnant and lactating women are likely to use and benefit from long-acting agents. We focus on long-acting formulations of small molecules (rather than biologics such as monoclonal antibodies) and on several infections of global importance (human immunodeficiency virus, tuberculosis, malaria, and hepatitis C). We discuss pregnancy pharmacokinetic/pharmacodynamic and potential safety and efficacy considerations pertaining to the use of long-acting agents in pregnancy and lactation. Finally, we summarize existing preclinical and pregnancy pharmacokinetic data that are available (or expected in the near future) for several agents that are under development or approved, and how key research gaps may be addressed.

publication date

  • November 21, 2022

Research

keywords

  • Hepatitis C
  • Lactation

Identity

Digital Object Identifier (DOI)

  • 10.1093/cid/ciac659

PubMed ID

  • 36410383

Additional Document Info

volume

  • 75

issue

  • Supplement_4